ADHD Drugs May Get Black Box
A sharply divided panel of experts recommended that medications for attention deficit hyperactivity disorder carry the Food and Drug Administration's strictest warning about potential risks of heart damage and sudden death.
By a vote of 8 to 7, with one abstention, an advisory committee to the FDA said these drugs, including Novartis' (NVS) Ritalin and Shire Pharmaceuticals Group's (SHPGY) Adderall contain so-called black box warnings to alert patients and physicians to the possible problems. The FDA isn't bound by its advisory panels' recommendations. The vote came during a meeting when medical experts were being asked to determine "research approaches" that could be used to study whether ADHD drugs increase the risk of heart problems, according to an FDA description of the gathering. Although the FDA "has received case reports" of sudden death and heart damage, "these reports by themselves do not establish a causal relationship" between ADHD drugs and cardiac problems, said Gerald J. Dal Pan, director of the FDA's office of drug safety, in a written introduction to the advisory panel meeting. However, panel members decided to act more emphatically, recommending that the black box warning be instituted. If subsequent tests prove there's no link between the drugs and heart disease, the black box warning could be removed, said one panel member according to Bloomberg News. The FDA identified 11 brand-name ADHD drugs and some generics. Some brand-name drugs are closely related -- such as Shire's Adderall and Adderall XR -- and most are stimulants. The nonstimulant is Strattera from Eli Lilly (LLY). Other prominent brand names include Concerta from Johnson & Johnson (JNJ) and Focalin from Novartis. The label for each ADHD drug has an assortment of warnings. For example, Strattera has a black box warning that refers to reports of suicidal thinking among children and adolescents. Labels for Adderall and Adderall XR warn about abusing amphetamines, which could lead to sudden death and heart damage.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
-
Sanofi Nearer to Genyzme Bid
The Wall Street Journal.
-
Fed's Beige Book: Activity continued to increase, "steady" in some districts
Calculated Risk
-
Amazon Doubles Down on the Kindle
BusinessWeek Online
-
Russia Moves to Sell Shares in State Companies
New York Times
-
Fixed retirement age to be axed
BBC
-
On midterm campaign trail, Obama mixes populist appeal with wooing of big donors
Washington Post
-
Behind Disney's Digital Shopping Spree
BusinessWeek Online
-
Blinder and Zandi Paper
Calculated Risk
-
Europe's Two-Speed Economy: North Vs. South
New York Times
-
Adobe to Launch Tender Offer for Day Software
The Wall Street Journal.
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS: Now any level of investor can trade right alongside a Wall Street pro — and enjoy 24/7 access to his portfolio! Learn More
RealMoney Silver: Get Doug Kass's exclusive trading diary + 5 of TheStreet's top premium services including Action Alerts PLUS and RealMoney — all on one streamlined page. Learn More
Stocks Under $10: Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
OptionsProfits: Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Breakout Stocks: Find tomorrow's household names today. Bryan Ashenberg finds hidden gems in exciting up-and-coming markets that he believes are ready to break out! Learn More
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,497.88 | 1,106.13 | 2,264.56 | 30.01 |
Oil *
75.81
|
|
DOWN
39.81 |
DOWN
7.71 |
DOWN
23.69 |
DOWN
0.46 |
10 Yr
3.00%
SPDR Gold
113.78
|
|
-0.38%
|
-0.69%
|
-1.04%
|
-1.51%
|
Data delayed 20 minutes |

Connect with TheStreet